Summary Using an under agarose migration (UAM) assay, we studied lymphokine-activated killer (LAK)-attractant activity in cultured conditioned medium of tumour tissues after chemotherapy as a possible mechanism of enhanced LAK cell accumulation into tumour tissues after chemotherapy. BMT-11 is a fibrosarcoma developed in C57BL/6 mice. The conditioned medium of BMT-11 tumour tissues obtained from mice treated with various anti-cancer drugs had chemotactic activity for LAK cells (LAK-attractant activity). mRNA expression of interleukin (IL)-la, IL-6, IL-8, interferon (IFN)-y, and tumour necrosis factor (TNF)-a was observed in untreated tumour tissues, which were not enhanced by cyclophosphamide treatment. mRNA expression of TGF-,IB was not detected in untreated tumour tissues by reverse transcription-polymerase chain reaction (RT-PCR), but was detected in tumour tissues treated with cyclophosphamide. Recombinant human TGF-,B1 showed LAK-attractant activity at a concentration of 0.1 ng ml-1 and 1 ng ml-', whereas fresh splenocytes were not attracted by TGF-f,1. Anti-TGF-,B1 antibody inhibited LAK-attractant activity in the conditioned medium of tumour tissues treated with cyclophosphamide to approximately 35% that of control at 100 Mg ml -l. These findings indicate that TGF-,13 produced in the tumour tissues of mice treated with anticancer drugs could be a LAK attractant. By a 4 h 51 Cr release assay of natural killer cell-resistant BMT-11 tumour cells, we observed that TGF-,B1 at a concentration from 0.01 ng ml-1 to 10 ng ml-1 did not inhibit LAK activity in an effector phase. Taken together, we suggest that TGF-,B1 produced in tumour tissues after chemotherapy participates in gathering transferred LAK cells and contributes to the therapeutic effects of transferred LAK cells.
Lymphokine-activated killer (LAK) cells are interleukin (IL)-2-activated natural killer (NK) or T cells, and show strong cytotoxic activity against a broad variety of tumour cells, including NK-resistant tumour cells (Grimm et al., 1982; Rosenberg et al., 1985) . It was much expected that LAK cells would be a new potent anti-tumour effector in adoptive immunotherapy; however, adoptive immunotherapy with LAK cells was found to produce only limited clinical effects on human cancers, including melanomas and renal cell carcinomas. One of the reasons for this discrepancy is that transferred LAK cells are unable to accumulate efficiently at tumour sites. Many investigators studying LAK cell distribution in vivo agreed that LAK cells are distributed at the liver and spleen 24 h after i.v. transfer. However, accumulation of LAK cells at the tumour site is less than 5% of all transferred cells (Lotze et al., 1980; Hosokawa et al., 1988; Maghazachi et al., 1988; Ames et al., 1989; Felgar et al., 1990; Kawata et al., 1990; Futami et al., 1991) . The poor tumour-specific accumulation of LAK cells might be due to a lack of specific recognition of tumour cells. Some trials have been performed to give LAK cells specificity for tumour recognition using bispecific antibody (Nitta et al., 1990 (Nitta et al., , 1991 . We previously reported that cancer chemotherapy before LAK cell transfer increased effects of LAK adoptive immunotherapy synergistically, and that transferred LAK cell accumulation in tumour tissues was enhanced in mice by treatment with cancer chemotherapeutic agents (Kawata et al., 1990; Hosokawa et al., 1992) . Therefore, we have attempted to clarify mechanisms responsible for the enhanced accumulation at the tumour tissues of LAK cells transferred after chemotherapy from the viewpoint of chemotaxis for LAK cells.
Materials and methods Animals Female C57BL/6 mice, 8-12 weeks of age, were obtained from Japan SLC (Hamamatsu, Japan). The mice were maintained in the specific pathogen-free animal facility at the Institute for Animal Experiments, Hokkaido University School of Medicine. Tumour BMT-1 1 tumour is a transplantable fibrosarcoma induced by 3-methylcholanthrene in a C57BL/6 mouse (Ishikawa et al., 1987; Okada et al., 1990) . The tumour cells were maintained as a monolayer culture in Eagle's minimum essential medium (EMEM) with 10% heat-inactivated fetal bovine serum (FBS).
Cytokines and antibodies Purified recombinant human (rh) IL-2 was the generous gift of Shionogi Pharmaceutical (Osaka, Japan), and has specific activity greater than 106 U mg-1 protein. Purified recombinant human (rh) TGF-,B1 was obtained from Chemicon Preparation of tymphokine-activated killer cells Spleens were removed from normal C57BL/6 mice. A cell suspension was prepared by disrupting the spleens in a loosefitting glass homogeniser with RPMI-1640 containing 10% heat-inactivated FBS (10% FBS-RPMI). After the red blood cells had been lysed by Tris-buffered ammonium chloride, the cell suspension was washed three times in cold 10% FBS-RPMI. The spleen cells (106 ml-') were cultured with IL-2 (1000 U ml-') in 100 mm tissue culture dishes (Corning 25020) in 20 ml of 10% FBS-RPMI at 37°C in a carbon dioxide incubator. After 5 days of culture, viable cells were harvested and their cytotoxicity was determined by a 4 h 5'Cr release assay of NK cell-resistant cultured BMT-11 tumour cells.
Preparation of conditioned medium of tumour tissue Mice were inoculated subcutaneously with BMT-11 cells (1 x 106) on day 0. Cyclophosphamide (CPM) (Shionogi Pharmaceutical, Osaka, Japan), 150 mg kg-' i.v.; bleomycin (Nippon Kayaku, Tokyo, Japan), 40 mg kg-' i.p.; doxorubicin (Kyouwa Hakko, Tokyo, Japan), 10 mg kg-' i.v.; mitomycin C (Kyouwa Hakko), 2 mg kg-' i.v.; cisplatinum (Nippon Kayaku), 5 mg kg-' i.p.; or pepleomycin (Nippon Kayaku), 20 mg kg-' i.p. was administered as chemotherapy on day 10 when the tumour had grown to an average diameter of 5 mm. Four days after the chemotherapy mice were sacrificed. To obtain conditioned medium (CM), minced tumour tissues were incubated in serum-free medium (ASF 103, Ajinomoto, Tokyo, Japan). After 24 h of culture at 37°C in a 5% carbon dioxide humid air incubator, the supematant was harvested. After centrifugation at 20 000 g for 60 min, the supernatant was passed through 0.45 gm pore filters and was used as CM of tumour tissue.
Under agarose migration (UAM) assay The UAM assay is a simple method for measuring chemotaxis and spontaneous migration of leucocytes (Nelson et al., 1975; Chenoweth et al., 1979) . Agarose (electrophoresis purity reagent, Bio-Rad, CA, USA) was dissolved in distilled water at a concentration of 2% by heating in a boiling water bath for 15 min. After cooling to 48°C in a water bath, the agarose was mixed with an equal volume of prewarmed 2 x ASF103. An aliquot of 15 ml of the agarose medium was delivered to a gelatin-coated culture dish and allowed to harden. Six series of three wells 2.5 mm in diameter and spaced 3 mm apart were cut in each plate using a stainless steel punch. The centre well of each three-well series received 10 M1 of the cell suspension containing 2 x 105 LAK cells. The outer wells received 10 p1 of each sample or human recombinant TGF-ll and the inner wells received 10 p1 of ASF103 as non-chemotactic control medium. The dishes were incubated at 37°C in a 5% carbon dioxide humid air incubator. After 3 h incubation quantification of migration was done by measurement of the linear distance the cells had moved from the margin of the well towards the sample (distance A) and the linear distance the cells had moved from the margin of the well toward the control medium (distance B: random migration) under the microscope. A-B was represented as LAK-attractant activity of the sample. For the neutralisation of LAK-attractant activity of the sample with anti-human TGF-fil antibody, each concentration of anti-human TGF-,ll antibody was added into the outer well with the sample.
Reverse transcription-polymerase chain reaction (RT-PCR) Total RNAs were extracted from the tumour tissues untreated or treated with anti-cancer drugs. Each RNA sample (5 pg underwent cDNA synthesis in 50 pl of reaction mixture containing 75 mM potassium chloride, 50 mM Tris-HCI (pH 8.3), 3 mm magnesium chloride, 10 mM dithiothereitol, 0.5 mM each dNTP, 2 ig ml-' random primer, and 1000 U MMLV reverse transcriptase (Gibco, MD, USA) by incubation at 37°C for 1 h. PCR amplification of cDNA (5 ,lt) was performed in 50 1l containing 50 mM potassium chloride, 10 mM Tris-HCl (pH 9.0), 2.5 mm magnesium chloride, 0.1% Triton X-100, 200 /M each dNTP, 10 mM each specific primer and 1 U Taq polymerase (Gibco BRL, MD, USA). The primer pairs used were IL-la (Lomedico et al., 1984) , IL-6 (Chiu et al., 1988) , IL-8 (Ohmori et al., 1990) , TNF-oa (Pennica et al., 1985) , IFN-y (Gray et al., 1983) , TGF-P1 (Rugo et al., 1992) and ,B-actin (Tokunaga et al., 1986) . Table I shows the primer sequences. The primer sequences were chosen from separate DNA exons of the gene. Expected sizes of amplified DNA fragments were 341, 149, 225, 468, 408, 360 and 478 bp for IL-la, IL-6, IL-8, TNF-a, IFN-y, TGF-,B1, and f-actin respectively. The reactions were run for 25 and 35 cycles using a thermal cycler as follows: 1 min at 94°C, 1 min at 60°C and 2 min at 72°C. Aliquots of 9 pl of each PCR sample were mixed with 1 Ml of gel roading buffer, electrophoresed through 1 % agarose gel and stained with ethidium bromide.
Bioassay of TGF-f3 activity
In vitro bioassay to detect TGF-,B activity was based on the method described by Lucas et al. (1991) The production of TGF-1 in the CMs of BMT-JJ tumour tissues treated with anti-cancer drugs Table III shows the activities of TGF-# in the CMs of tumour tissues after chemotherapy. The tumour tissues treated with CPM, CDDP and PEP produced 17.7 ng ml-', 25.3 ng ml-' and 40.3 ng ml-1 of TGF-f respectively, whereas we could detect no TGF-# activity in the CMs of untreated tumour tissues.
IL-6 P-Actin aApproximately 1 x 106 BMT-1 1 cells were implanted subcutaneously on day 0. Anti-cancer drugs were administered on day 10 when tumours had grown to an average diameter of 5 mm. Four days after chemotherapy mice were sacrificed and minced tumour tissues were incubated in serum-free medium for 24 h. The supernatant was harvested from the culture dishes, centrifuged at 20 000 x g for 60 min and passed through 0.45-pm-pore size filters. bDistance A represents the linear distance that LAK cells moved from the margin of the well towards the sample. cDistance B represents the linear distance that LAK cells moved from the margin of the well towards the control medium. dStatistically significant difference between distances A and B. ep<0.001 vs conditioned medium of BMT-1 1 tumour tissues from untreated mice. aApproximately 1 x 106 BMT-11 cells were implanted subcutaneously on day 0. Anti-cancer drugs were administered on daylO when tumours had grown to an average of 5 mm. Four days after chemotherapy mice were sacrificed and minced tumour tissues were incubated in serum-free medium for 24 h. The supernatant was harvested from the culture dishes, centrifuged at 20 000 x g for 60 min and passed through 0.45-,um-pore size filters. b The production of TGF-,B in CM was examined by bioassay using MvlLu cells.
LAK-attractant activity of recombinant humnan TGF-/31
We examined whether or not TGF-/31 showed LAKattractant activity. The results indicate that recombinant human TGF-,B1 showed definite LAK-attractant activity as seen in Figure 3 . The LAK-attractant activity of TGF-,Bl increased in a dose-dependent manner up to 1 ng ml-', which, however, decreased at higher concentrations than 10 ng ml-'.
The effects oJfanti-TGF-/31 antibody on LAK-attractant activity in CM prepared from tumour tissues treated wtith (>lclophosphamide As we detected TGF-,lB activity in CPM-treated tumour tissue CM, we next examined whether or not TGF-/1 in CM prepared from tumour tissues treated with CPM participates in LAK-attractant activity. The effects of anti-TGF-/3l antibody have been tested on LAK-attractant activity of the CM. Anti-TGF-/31 antibody abrogated LAK-attractant activity in the CM of tumour tissues treated with CPM to 800/ of control at a concentration of 1 ,ug ml-', and to 35% of control with 100 pg ml-' (Figure 4) . The same concentration of control IgY could not suppress the LAK-attractant activity of CMs.
The ef.fcts of TGF-/31 on LAK cell ci'totoxicity From the findings mentioned above, it is revealed that TGF-/31 produced in tumour tissues after chemotherapy could be a LAK-attractant. However, TGF-f is known to suppress the host immune system. There were many reports that TGF-f31
inhibited LAK activity in an induction phase, but we did not know whether TGF-/31 inhibited LAK cell cytotoxic activity in an effector phase or not. We measured LAK activity by a 4 h 5'Cr release assay against NK-resistant BMT-1 1 tumour cells in the presence of TGF-/Jl at a concentration from 0.01 ng ml-' to 10 ng ml-' in an effector phase. At all concentrations of TGF-/3l, no effect on LAK cell cytotoxic activity was observed ( Figure 5 ). clarify the mechanism of production for TGF-#fI in tumour tissue after chemotherapy. TGF-#l is one of the inflammatory cytokines. Therefore it is speculated that inflammatory cytokines such as IL-1. IL-6 and TNF-x will be produced in tumour tissues by chemotherapy. and that they will induce the production of TGF-fl from host reactive cells in combination with cytotoxic effects of anti-cancer drugs. (Lotze et al.. 1980; Hosokawa et al., 1988 : Maghazachi et al., 1988 : Ames et al.. 1989 : Felgar et al.. 1990 Futami et al.. 1991) . Therefore. effectiveness of LAK adoptive immunotherapy is thought to depend greatly on the accumulation in tumour tissues. We have previously reported that chemotherapy for tumour-bearing mice enhanced the accumulation of LAK cells in tumour tissues (Hosokawara et al.. 1988 : Kawata et al.. 1990 : Hosokawa et al.. 1992 . Pockaj et al. (1994) have also reported that CPM administration before tumour infiltrating lymphocyte (TIL) and IL-2 therapy and the administration of large numbers of TILs improved the frequency of TIL localisation to tumour in human clinical study. This report is able to clarify the mechanism by which these chemotherapies enhance the accumulation of LAK cells in tumour tissues.
